Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynasil Corporation of America announced that its contract research subsidiary, RMD, has received three grants totaling $3.5m under the National Institute of Health's Small Business Innovation Research (SBIR) Program.
Subscribe to our email newsletter
"RMD’s world-class research continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil’s Chairman of the Board, Chief Executive Officer and President.
"RMD is developing advanced radiation detection materials and predictive instrumentation for the National Institute of Health that will deliver lower cost, next generation medical imaging systems and, if developed to a commercial product, predict the onset of shock."
Two of these awards are for RMD’s cutting edge research in hemodynamics. The first award focuses on providing first responders and emergency physicians with a simple, inexpensive, easy to use system that predicts the onset of hemorrhagic shock before the patient’s vital signs reach a critical stage.
The third award will concentrate on providing a critically needed tool to monitor the development of grafted skin, bone and muscle both prior to reconstructive surgery as well as during post-surgical recovery.
"These tools emphasize RMD’s commitment to providing instruments that will not only save lives but improve the quality of people’s lives as well," Sulick continued.
"The Phase II research projects RMD are undertaking through these SBIR Programs exemplify some of the world’s most demanding medical needs," said Kanai Shah, Ph.D., President of Dynasil’s RMD subsidiary.
"These Phase II grants capitalize on our technical and scientific capability in the development of scintillation materials and instrumentation. Dynasil is proud to partner with the National Institute of Health on these initiatives."